Diabetes Drug Fights Breast Cancer
Metformin Kills Breast Cancer Stem Cells, May Fight Many Cancers
Sept. 14, 2009 - The next breakthrough breast cancer treatment may be
a diabetes drug already on the shelves of nearly every
The drug is metformin, available
generically and under brand names such as Glucophage and Fortamet. A growing body of evidence suggests that
diabetes patients taking metformin are less likely to get cancer, and have better
outcomes if they do get cancer, than those not taking the drug.
Now Harvard researcher Kevin Struhl, PhD, and colleagues find that metformin
can kill breast
cancer stem cells, thought to be the cells responsible for breast cancer
spread and recurrence.
And in mice carrying human breast cancers, metformin made standard
chemotherapy vastly more effective. Mice treated with the combination remain
cancer-free for four months, unlike mice treated with either drug alone.
"We have discovered new properties of metformin that can be of some use in
cancer treatment and even prevention," Struhl said at a news conference held to
announce the findings.
While his current study looked at metformin's effects on breast cancer,
Struhl says the drug may affect other types of cancer as well.
"Although our studies were pretty much done on breast cancer cells, a lot of
the principles are not specific just to breast cancer," Struhl said. "A lot of
data shows lower cancer risk -- not just breast cancer -- in people taking
metformin for diabetes."
Metformin Kills Cancer Stem Cells
What's so special about yet another drug that kills cancer cells in
For one thing, the kind of cancer cells metformin targets are cancer stem
cells, which are resistant to standard chemotherapy.
"This is the first time it's been shown that metformin may have an effect on
these very resistant cancer cells. It is very exciting research," Dana-Farber
Cancer Institute researcher Jennifer A Ligibel, MD, said at the news
The very existence of cancer stem cells has been debated. That debate is now
"water under the bridge," Frank Rauscher, PhD, suggested at the news
conference. Rauscher, a cancer researcher at the Wistar Institute, is
editor-in-chief of Cancer Research, which published the Struhl study in
today's advance online edition.